Improving treatments for young people with Hodgkin Lymphoma
Advancing novel therapeutics and translational science to close the survivorship gap in pediatric, adolescent and young adult (AYA) lymphoma
This study is looking for better ways to treat young people with Hodgkin Lymphoma by trying out new therapies and making it easier for them to join clinical trials, all with the hope of helping them live longer and feel better during treatment.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Emory University NIH-funded |
| Lab location | 1 site (Atlanta, United States) |
| Project ID | NIH-10782090 on NIH RePORTER |
What this research studies
This research focuses on addressing the survival gap in adolescents and young adults (AYA) with Hodgkin Lymphoma by exploring new therapies such as antibody-drug conjugates and immunotherapies. The project aims to enhance access to clinical trials for this age group and develop better treatment strategies that consider individual tumor biology and patient characteristics. By collaborating with national trial networks, the research seeks to incorporate innovative therapies into standard care for both newly diagnosed and relapsed patients. The goal is to improve long-term survival and reduce the side effects associated with traditional chemotherapy and radiation.
Who could benefit from this research
Good fit: Ideal candidates for this research include adolescents and young adults diagnosed with Hodgkin Lymphoma, particularly those who may have limited access to current treatment options.
Not a fit: Patients with other types of cancers or those outside the adolescent and young adult age range may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and less harmful treatments for young patients with Hodgkin Lymphoma.
How similar studies have performed: Previous research has shown promise in using immunotherapy and targeted therapies for Hodgkin Lymphoma, indicating that this approach could be beneficial.
Where this research is happening
Atlanta, United States
- Emory University — Atlanta, United States (Active)
Researchers
- Principal investigator: Castellino, Sharon Marie — Emory University
- Study coordinator: Castellino, Sharon Marie
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.